Involvement of target gene polymorphisms in 5-fluorouracil toxicity: A case report

Pharmacology

Volumn 89, Issue 1-2, 2012, Pages 99-102

  Scalvini, Anna ^a   Ferrari, Vittorio ^a   Bodei, Serena ^a   Arcangeli, Giuseppina ^a   Consoli, Francesca ^a   Spano, PierFranco ^a   Sigala, Sandra ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

5 Fluorouracil; Adverse effects; Pharmacogenomics

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CISPLATIN; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

5' UNTRANSLATED REGION; ADENOID CYSTIC CARCINOMA; ADULT; ANEMIA; ARTICLE; CASE REPORT; COLON ADENOCARCINOMA; CONTINUOUS INFUSION; DIARRHEA; DNA POLYMORPHISM; FEMALE; GENETIC VARIABILITY; HUMAN; LIVER METASTASIS; LIVER TOXICITY; LUNG METASTASIS; MALE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PANCYTOPENIA; PHARMACOGENOMICS; PRIORITY JOURNAL; RNA SPLICING; SINGLE NUCLEOTIDE POLYMORPHISM; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADULT; DIHYDROURACIL DEHYDROGENASE (NADP); FEMALE; FLUOROURACIL; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); POLYMORPHISM, SINGLE NUCLEOTIDE; RNA SPLICING; TERMINAL REPEAT SEQUENCES; THYMIDYLATE SYNTHASE;

EID: 84856896598     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000335784     Document Type: Article

References (26)

1. Huang RS, Ratain MJ: Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J Clin 2009; 59: 42-55.
2. Meyer UA: Pharmacogenetics - five decades of therapeutic lessons from genetic diversity. Nat Rev Genet 2004; 5: 669-676.
3. Huang RS, Dolan ME: Approaches to the discovery of pharmacogenomic markers in oncology: 2000-2010-2020. Pharmacogenomics 2010; 11: 471-474.
4. Schwab M, Zanger U, Marx C, Schaeffeler E, Klein K, Dippon J, Kerb R, Blievernicht J, Fischer J, Hofmann U, Bokemeyer C, Eichelbaum M, German 5-FU Toxicity Study Group: Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: A prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol 2008; 26: 2131-2138.
5. Ajani J: Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers. Cancer 2006; 107: 221-231.
6. Walko CM, Lindley C: Capecitabine: A review. Clin Ther 2005; 27: 23-44.
7. Aguilar B, Rojas JC, Collados MT: Metabolism of homocysteine and its relationship with cardiovascular disease. J Thromb Thrombolysis 2004; 18: 75-87.
8. Chua W, Goldstein D, Lee CK, Dhillon H, Michael M, Mitchell P, Clarke SJ, Iacopetta B: Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer. Br J Cancer 2009; 101: 998-1004.
9. Diasio RB, Johnson MR: The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil. Pharmacology 2000; 61: 199-203.
10. Huang RS, Ratain MJ: Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J Clin 2009; 59: 42-55.
11. Horie N, Aiba H, Oguro K, Hojo H, Takeishi K: Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′ -terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 1995; 20: 191-197.
12. Kawakami K, Salonga D, Park JM, Danenberg KD, Uetake H, Brabender J, Omura K, Watanabe G, Danenberg PV: Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. Clin Cancer Res 2001; 7: 4096-4410.
13. Goyette P, Sumner JS, Milos R, Duncan AM, Rosenblatt DS, Matthews RG, Rozen R: Human methylenetetrahydrofolate reductase: Isolation of cDNA, mapping and mutation identification. Nat Genet 1994; 7: 195-200.
14. Van Der Put NM, Gabreels F, Stevens EM, Smeitink JA, Trijbels FJ, Eskes TK, Van den Heuvel LP, Blom HJ: A second common mutation in the methylenetetrahydrofolate reductase gene: An additional risk factor for neural-tube defects? Am J Hum Genet 1998; 62: 1044-1051.
15. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R: A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998; 64: 169-172.
16. Cohen V, Panet-Raymond V, Sabbaghian N, Morin I, Batist G, Rozen R: Methylenetetrahydrofolate reductase polymorphism in adVanced colorectal cancer: A novel genomic predictor of clinical response to fluoropyrimidine- based chemotherapy. Clin Cancer Res 2003; 9: 1611-1615.
17. Etienne MC, Formento JL, Chazal M, Francoual M, Magné N, Formento P, Bourgeon A, Seitz JF, Delpero JR, Letoublon C, Pezet D, Milano G: Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in adVanced colorectal cancer patients. Pharmacogenetics 2004; 14: 785-792.
18. Wisotzkey JD, Toman J, Bell T, Monk JS, Jones D: MTHFR (C677T) polymorphisms and stage III colon cancer: Response to therapy. Mol Diagn 1999; 4: 95-99.
19. Wei X, McLeod HL, McMurrough J, Gonzalez FJ, Fernandez-Salguero P: Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest 1996; 98: 610-615.
20. Ridge SA, Sludden J, Wei X, Sapone A, Brown O, Hardy S, Canney P, Fernandez-Salguero P, Gonzalez FJ, Cassidy J, McLeod HL: Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer. Br J Cancer 1998; 77: 497-500.
21. Lee W, Lockhart AC, Kim RB, Rothenberg ML: Cancer pharmacogenomics: Powerful tools in cancer chemotherapy and drug development. Oncologist 2005; 10: 104-111.
22. De Mattia E, Toffoli G: C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation. Eur J Canc 2009; 45: 1333-1351.
23. Etienne MC, Ilc K, Formento JL, Laurent- Puig P, Formento P, Cheradame S, Fischel JL, Milano G: Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: Relationships with 5-fluorouracil sensitivity. Br J Cancer 2004; 90: 526-534.
24. Sohn KJ, Croxford R, Yates Z, Lucock M, Kim YI: Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. J Natl Cancer Inst 2004; 96: 134-144.
25. Pullarkat ST, Stoehlmacher J, Ghaderi V, Xiong YP, Ingles SA, Sherrod A, Warren R, Tsao-Wei D, Groshen S, Lenz HJ: Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 2001; 1: 65-70.
26. Lecomte T, Ferraz JM, Zinzindohoue F, Loriot MA, Tregouet DA, Landi B, Berger A, Cugnenc PH, Jian R, Beaune P, Laurent-Puig P: Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res 2004; 10: 5880-5888.